ReviewInfectious diseases & immunity2025
HBsAg loss in HIV/HBV coinfected patients: Hepatitis B cure insights and implications.
Review in Infectious diseases & immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV (human immunodeficiency virus)/HBV (hepatitis B virus) coinfection remains a significant public health challenge. HIV infection affects the natural course of chronic HBV infection, with HIV/HBV coinfected patients experiencing higher liver-related morbidity, hospitalization rates, and mortality than those with HBV monoinfection. Surprisingly, an increasing number of studies have shown that hepatitis B surface antigen (HBsAg) clearance rates in HIV/HBV coinfection can reach over 10%, which is significantly higher than in HBV monoinfection. In this review, we summarize the predictive factors for HBsAg clearance observed in HIV/HBV coinfection, including baseline HBsAg levels, baseline HBV DNA levels, baseline CD4+T cell-counts, and immune reconstitution inflammatory syndrome-related hepatic flare. Based on current evidence, we further discuss a potential mechanism for HBsAg clearance: HIV-induced immunodeficiency, particularly the depletion of CD4+ T cells, may unexpectedly disrupt preexisting HBV-specific tolerance. After antiretroviral therapy (ART) in HIV/HBV coinfected individuals, partial immune system reconstitution occurs, and the reconstituted immune system, no longer tolerized by HBV, effectively clears HBV-infected hepatocytes, triggering transient hepatitis and ultimately achieving a functional cure through HBsAg clearance. Additionally, emerging data suggest that the underlying immunological mechanisms of HBsAg clearance in HIV/HBV coinfection may primarily involve: PD-1/PD-L1 pathway inhibition, cytokine induction promoting immune cell recruitment and an inflammatory environment, and natural killer (NK) cell functional remodeling. These collective observations highlight the important role of immune modulation in HBV clearance, providing insights that can facilitate the development of a functional HBV cure. Identifying the mechanisms involved in HBsAg loss in HIV/HBV patients may facilitate the development of drugs that mimic these anti-HBV responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.